$PBYI
PUMA BIOTECHNOLOGY, INC.

2015 Q3 Form 10-Q Financial Statement

#000156459015010147 Filed on November 09, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q3
Revenue $0.00 $1.800M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.810M $5.530M $3.870M
YoY Change 127.65% 41.79% 71.24%
% of Gross Profit
Research & Development $51.92M $59.38M $32.09M
YoY Change 61.79% 69.65% 165.91%
% of Gross Profit
Depreciation & Amortization $200.0K $190.0K $160.0K
YoY Change 25.0% 26.67% 45.45%
% of Gross Profit
Operating Expenses $60.73M $64.91M $35.96M
YoY Change 68.89% 66.85% 150.92%
Operating Profit -$60.73M -$64.91M
YoY Change 66.85%
Interest Expense $320.0K $210.0K $110.0K
YoY Change 190.91% 200.0% 1000.0%
% of Operating Profit
Other Income/Expense, Net -$2.000K $10.00K $0.00
YoY Change -83.61% -100.0%
Pretax Income -$60.42M -$64.69M -$35.84M
YoY Change 68.58% 66.56% 150.98%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$60.42M -$64.69M -$35.84M
YoY Change 68.56% 66.55% 150.96%
Net Earnings / Revenue -3594.11%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.871M -$2.012M -$1.190M
COMMON SHARES
Basic Shares Outstanding 32.15M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $247.8M $282.4M $153.9M
YoY Change 61.01% 58.3% 60.98%
Cash & Equivalents $23.60M $59.84M $28.26M
Short-Term Investments $224.2M $222.5M $125.6M
Other Short-Term Assets $6.900M $5.400M $4.500M
YoY Change 53.33% 54.29% 25.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $1.800M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $254.7M $287.8M $160.1M
YoY Change 59.09% 56.75% 44.79%
LONG-TERM ASSETS
Property, Plant & Equipment $2.500M $2.600M $1.900M
YoY Change 31.58% 36.84% 17.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.40M $12.00M $10.00M
YoY Change 44.0% 14.29% 244.83%
Total Long-Term Assets $16.90M $14.56M $12.00M
YoY Change 40.83% 16.49% 164.73%
TOTAL ASSETS
Total Short-Term Assets $254.7M $287.8M $160.1M
Total Long-Term Assets $16.90M $14.56M $12.00M
Total Assets $271.6M $302.4M $172.1M
YoY Change 57.82% 54.19% 49.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.800M $10.44M $18.40M
YoY Change -46.74% -44.45% 89.11%
Accrued Expenses $15.50M $15.66M $10.90M
YoY Change 42.2% 72.03% 14.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.30M $26.10M $29.40M
YoY Change -13.95% -6.46% 52.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.500M $1.500M $1.100M
YoY Change 36.36% 36.36% 0.0%
Total Long-Term Liabilities $1.500M $1.500M $1.100M
YoY Change 36.36% 36.36% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.30M $26.10M $29.40M
Total Long-Term Liabilities $1.500M $1.500M $1.100M
Total Liabilities $26.80M $27.58M $30.50M
YoY Change -12.13% -4.89% 49.88%
SHAREHOLDERS EQUITY
Retained Earnings -$458.8M
YoY Change
Common Stock $673.5M $375.5M
YoY Change 72.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $244.8M $274.8M $141.6M
YoY Change
Total Liabilities & Shareholders Equity $271.6M $302.4M $172.1M
YoY Change 57.82% 54.22% 49.51%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q3
OPERATING ACTIVITIES
Net Income -$60.42M -$64.69M -$35.84M
YoY Change 68.56% 66.55% 150.96%
Depreciation, Depletion And Amortization $200.0K $190.0K $160.0K
YoY Change 25.0% 26.67% 45.45%
Cash From Operating Activities -$36.87M -$34.55M -$24.32M
YoY Change 51.6% 98.91% 102.67%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K -$360.0K -$120.0K
YoY Change 25.0% 12.5% 50.0%
Acquisitions
YoY Change
Other Investing Activities -$4.590M -$67.76M -$2.650M
YoY Change 73.21% -24.99% -215.22%
Cash From Investing Activities -$4.750M -$68.12M -$2.770M
YoY Change 71.48% -24.85% -224.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.370M 7.040M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -36.87M -34.55M -24.32M
Cash From Investing Activities -4.750M -68.12M -2.770M
Cash From Financing Activities 5.370M 7.040M 0.000
Net Change In Cash -36.25M -95.63M -27.09M
YoY Change 33.81% -11.47% 125.75%
FREE CASH FLOW
Cash From Operating Activities -$36.87M -$34.55M -$24.32M
Capital Expenditures -$150.0K -$360.0K -$120.0K
Free Cash Flow -$36.72M -$34.19M -$24.20M
YoY Change 51.74% 100.53% 103.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
318000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.87
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-458781000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
60733000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60733000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
205133000
CY2015Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
190.00
us-gaap Depreciation And Amortization
DepreciationAndAmortization
568000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
438000
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
179000
us-gaap Share Based Compensation
ShareBasedCompensation
73254000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
73254000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60268000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
205133000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
129440000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26908000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
232041000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129440000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14941000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14781000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43044000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28263000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32303203
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
149000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26908000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
81.33
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4425000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1893000
CY2015Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
17005000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2449000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
86.83
CY2014Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
7764000
CY2014Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2541000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
334000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3735000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
56000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
25000
us-gaap Share Based Compensation
ShareBasedCompensation
22779000
us-gaap Increase Decrease In Contract Receivables Net
IncreaseDecreaseInContractReceivablesNet
-1760000
us-gaap Increase Decrease In Contract Receivables Net
IncreaseDecreaseInContractReceivablesNet
-8053000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
706000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
5593000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5214000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7756000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-13896000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2332000
us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
-183000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-121437000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-58742000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
943000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
554000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
3097000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-85479000
CY2014Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.35
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
2.29
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18942
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
102.46
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include accrued expenses for the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates used to record accrued expenses and to value the stock-based compensation will occur in the near term. </p></div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
89.17
CY2015Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36800000
CY2015Q2 us-gaap Reimbursement Revenue
ReimbursementRevenue
1800000
CY2015Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
8813000
CY2015Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2610000
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
16414000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
81000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24956000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10449000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
73254000
CY2015Q3 pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.77
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk: </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at September&#160;30, 2015, were approximately $27.8&nbsp;&nbsp;million. The Company does not believe it is exposed to any significant credit risk due to the quality of the financial instruments in which the money is held. Pursuant to the Company&#8217;s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor&#8217;s Corporation and Moody&#8217;s Investors Service at the time of purchase. </p></div>
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2015Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
27800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2014Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
16299000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3482000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1325000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22779000
pbyi Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
0.76
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18942
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
102.46
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3978126
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1402786
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
214110
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
720253
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2291
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4444258
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2802984
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1641274
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
89.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
153.65
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
188.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
36.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
117.84
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.12
CY2015Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
150.43
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.87
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P9Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
431635000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
93368000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
80264000
CY2015Q3 pbyi Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
10135000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
70129000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2591565
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
977257
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
214110
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
61.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
110.20
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
90.95
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000

Files In Submission

Name View Source Status
0001564590-15-010147-index-headers.html Edgar Link pending
0001564590-15-010147-index.html Edgar Link pending
0001564590-15-010147.txt Edgar Link pending
0001564590-15-010147-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201511092103475872761.jpg Edgar Link pending
g201511092103480402762.jpg Edgar Link pending
g201511092104049342481.jpg Edgar Link pending
pbyi-10q_20150930.htm Edgar Link pending
pbyi-20150930.xml Edgar Link completed
pbyi-20150930.xsd Edgar Link pending
pbyi-20150930_cal.xml Edgar Link unprocessable
pbyi-20150930_def.xml Edgar Link unprocessable
pbyi-20150930_lab.xml Edgar Link unprocessable
pbyi-20150930_pre.xml Edgar Link unprocessable
pbyi-ex101_200.htm Edgar Link pending
pbyi-ex102_201.htm Edgar Link pending
pbyi-ex103_245.htm Edgar Link pending
pbyi-ex311_11.htm Edgar Link pending
pbyi-ex312_7.htm Edgar Link pending
pbyi-ex321_9.htm Edgar Link pending
pbyi-ex322_10.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending